PT1073738E - Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas - Google Patents
Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticasInfo
- Publication number
- PT1073738E PT1073738E PT99920731T PT99920731T PT1073738E PT 1073738 E PT1073738 E PT 1073738E PT 99920731 T PT99920731 T PT 99920731T PT 99920731 T PT99920731 T PT 99920731T PT 1073738 E PT1073738 E PT 1073738E
- Authority
- PT
- Portugal
- Prior art keywords
- nucleic acid
- methods
- present
- ion channel
- relates
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000004310 Ion Channels Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000007257 malfunction Effects 0.000 abstract 2
- 229910001414 potassium ion Inorganic materials 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98107268 | 1998-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1073738E true PT1073738E (pt) | 2005-01-31 |
Family
ID=8231794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99920731T PT1073738E (pt) | 1998-04-21 | 1999-04-21 | Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US6638736B1 (enExample) |
| EP (1) | EP1073738B1 (enExample) |
| JP (2) | JP2002512029A (enExample) |
| AT (1) | ATE278017T1 (enExample) |
| CA (1) | CA2323571A1 (enExample) |
| DE (1) | DE69920681T2 (enExample) |
| DK (1) | DK1073738T3 (enExample) |
| ES (1) | ES2230852T3 (enExample) |
| PT (1) | PT1073738E (enExample) |
| WO (1) | WO1999054463A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69920681T2 (de) * | 1998-04-21 | 2005-09-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Humaner k+ ionenkanal und therapeutische verwendungen davon |
| DE10025620A1 (de) * | 2000-05-24 | 2001-12-06 | Forschungsgesellschaft Genion | Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten |
| DE10224534A1 (de) | 2002-05-31 | 2003-12-11 | Juergen Dolderer | Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung |
| EP1805222B1 (en) | 2004-10-01 | 2011-02-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Antibodies directed to the mammalian eag1 ion channel protein |
| MX2007003865A (es) * | 2004-10-01 | 2009-06-17 | Ct Investig Y Estudios Del Ipn | Métodos para el diagnóstico temprano de infecciones virales y enfermedades inflamatorias o de la predisposición de un individuo a desórdenes proliferativos o hiperplasia. |
| AU2013201604B2 (en) * | 2007-04-13 | 2014-08-14 | Southern Research Institute | Anti-angiogenic agents and methods of use |
| ES2334084B1 (es) * | 2007-12-21 | 2011-01-24 | Inst Cientifico Tecnol Navarra | Marcadores geneticos para el pronostico de la esclerosis multiple. |
| US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
| TWI570415B (zh) * | 2015-10-02 | 2017-02-11 | A spring probe having an outer sleeve and a probe device having the spring probe | |
| EP3195727A1 (en) | 2016-01-22 | 2017-07-26 | Forschungsinstitut Fur Biologischen Landbau (FiBL) | Duddingtonia flagrans strain and feed additive formulation for biological pest control |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB9303210D0 (en) | 1993-02-17 | 1993-03-31 | Univ Manitoba | Cancer treatment |
| AU665341B2 (en) | 1990-12-18 | 1996-01-04 | Wellcome Foundation Limited, The | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| JP2000515498A (ja) * | 1996-07-02 | 2000-11-21 | ノバルテイス・コンシユーマー・ヘルス・エス・アー | 抗ヒスタミン化合物とテルペノイド化合物の組み合わせからなる局所組成物 |
| US6610827B1 (en) * | 1997-10-29 | 2003-08-26 | Elan Pharmaceuticals, Inc. | Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor |
| DE69920681T2 (de) * | 1998-04-21 | 2005-09-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Humaner k+ ionenkanal und therapeutische verwendungen davon |
-
1999
- 1999-04-21 DE DE69920681T patent/DE69920681T2/de not_active Expired - Lifetime
- 1999-04-21 DK DK99920731T patent/DK1073738T3/da active
- 1999-04-21 AT AT99920731T patent/ATE278017T1/de not_active IP Right Cessation
- 1999-04-21 PT PT99920731T patent/PT1073738E/pt unknown
- 1999-04-21 ES ES99920731T patent/ES2230852T3/es not_active Expired - Lifetime
- 1999-04-21 JP JP2000544795A patent/JP2002512029A/ja not_active Withdrawn
- 1999-04-21 WO PCT/EP1999/002695 patent/WO1999054463A2/en not_active Ceased
- 1999-04-21 EP EP99920731A patent/EP1073738B1/en not_active Expired - Lifetime
- 1999-04-21 CA CA002323571A patent/CA2323571A1/en not_active Abandoned
-
2000
- 2000-10-23 US US09/694,777 patent/US6638736B1/en not_active Expired - Fee Related
-
2002
- 2002-07-01 US US10/188,308 patent/US7364730B2/en not_active Expired - Fee Related
- 2002-07-01 US US10/188,296 patent/US7364845B2/en not_active Expired - Fee Related
- 2002-07-01 US US10/188,297 patent/US7314914B2/en not_active Expired - Fee Related
- 2002-07-01 US US10/188,341 patent/US7129207B2/en not_active Expired - Fee Related
-
2006
- 2006-11-30 US US11/633,085 patent/US20080020406A1/en not_active Abandoned
-
2009
- 2009-06-09 US US12/480,913 patent/US20100021467A1/en not_active Abandoned
- 2009-07-06 JP JP2009160236A patent/JP2009235091A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20030077735A1 (en) | 2003-04-24 |
| US20030087378A1 (en) | 2003-05-08 |
| DK1073738T3 (da) | 2005-01-24 |
| EP1073738A2 (en) | 2001-02-07 |
| ATE278017T1 (de) | 2004-10-15 |
| WO1999054463A3 (en) | 2000-04-20 |
| US7129207B2 (en) | 2006-10-31 |
| US7314914B2 (en) | 2008-01-01 |
| EP1073738B1 (en) | 2004-09-29 |
| US7364730B2 (en) | 2008-04-29 |
| DE69920681T2 (de) | 2005-09-08 |
| WO1999054463A2 (en) | 1999-10-28 |
| DE69920681D1 (de) | 2004-11-04 |
| US7364845B2 (en) | 2008-04-29 |
| CA2323571A1 (en) | 1999-10-28 |
| US20100021467A1 (en) | 2010-01-28 |
| US20030092120A1 (en) | 2003-05-15 |
| US20030087377A1 (en) | 2003-05-08 |
| ES2230852T3 (es) | 2005-05-01 |
| US6638736B1 (en) | 2003-10-28 |
| JP2009235091A (ja) | 2009-10-15 |
| JP2002512029A (ja) | 2002-04-23 |
| US20080020406A1 (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition | |
| Nakatsuji et al. | A commensal strain of Staphylococcus epidermidis protects against skin neoplasia | |
| Beug et al. | Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma | |
| Huehnchen et al. | A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice | |
| Li et al. | Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin | |
| Namyen et al. | Protective effects of melatonin on methamphetamine-induced blood–brain barrier dysfunction in rat model | |
| Shin et al. | Induction of microglial toll-like receptor 4 by prothrombin kringle-2: a potential pathogenic mechanism in Parkinson’s disease | |
| BR0312913A (pt) | Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo | |
| DE69738581D1 (de) | Menschliche dnase i hyperaktive varianten | |
| Shou et al. | Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells | |
| Hou et al. | The inhibitory effect of IFN-γ on protease HTRA1 expression in rheumatoid arthritis | |
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| IL169896A0 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
| Ma et al. | Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury | |
| Ahmed et al. | Combinatory Effects of Bone Marrow‐Derived Mesenchymal Stem Cells and Indomethacin on Adjuvant‐Induced Arthritis in Wistar Rats: Roles of IL‐1β, IL‐4, Nrf‐2, and Oxidative Stress | |
| PT1073738E (pt) | Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas | |
| Li et al. | USP21 regulates Hippo signaling to promote radioresistance by deubiquitinating FOXM1 in cervical cancer | |
| Jo et al. | Tat-HSP22 inhibits oxidative stress-induced hippocampal neuronal cell death by regulation of the mitochondrial pathway | |
| BRPI0407544A (pt) | derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem | |
| Pozzi et al. | MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression | |
| BR0215063A (pt) | Derivados de hidroxifenil-pirazol ativos como inibidores de cinase, processo para preparação dos mesmos e composições farmacêuticas compreendendo-os | |
| Liu et al. | Tankyrase-mediated ADP-ribosylation is a regulator of TNF-induced death | |
| Liu et al. | Proteinase 3 depletion attenuates leukemia by promoting myeloid differentiation | |
| Hu et al. | Anti-radiation damage effect of polyethylenimine as a toll-like receptor 5 targeted agonist | |
| Malone et al. | Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds |